OsteoRemedies announced FDA clearance for expanded indications of its Spectrum GV dual antibiotic bone cement for use in revision total hip arthroplasty procedures. The bone cement is now indicated for component fixation during revision THA and two-stage revision THA after initial infection. Dr. R. Michael Meneghini highlighted the importance of dual antibiotic coverage in high-risk patients, while Dr. James A. Browne emphasized the synergy and increased antibacterial activity with the addition of dual antibiotics in cement. This advancement provides a premixed option for dual antibiotic coverage in cement, offering added protection against periprosthetic joint infection.
Source link
OsteoRemedies receives FDA clearance for expanded indications of antibiotic bone cement
